Pneumonic pasteurellosis is a common disease of sheep and goats worldwide. It is caused by a bacterium known as Mannheimia haemolytica (previously known as Pasteurella haemolytica), affecting between 30% and 60% of the goat and sheep populations worldwide, leading to deaths. Mannheimia haemolytica is part of the commensal of the nasal mucosa but becoming pathogenic upon stress to the animals, particularly rainy, winter and summer seasons.
This disease can be controlled by vaccination. Intranasal vaccine uses the concept of enhancing the local immunity of the respiratory tract to prevent infection. Therefore, antibodies are produced and stay in the respiratory tract to protect the tract from infection.
Intranasal vaccination against pneumonic pasteurellosis proved effective in protecting goats and sheep against pneumonic pasteurellosis. Studies have shown that the vaccine could protect 95% of goats and sheep from experimental infection while field trials revealed only 2% infection rate. It is advisable to vaccinate goats and sheep twice a year against pneumonic pasteurellosis prior to the start of stressful seasons, which are the rainy or monsoon seasons in the tropics or winter and summer seasons in the temperate countries.
STVac has been shown to be effective in protecting
small ruminants such as goats and sheep from
bacterial infections that cause pneumonia.
Through field trial that we conducted in selected localities, STVac has been PROVEN to be able to reduce mortality due to the disease by 98%.
STVac vaccine already been purchased and transferred exclusively to Bio-Angle Vacs for commercialization.
Mortality Rate before and after using STVac for 4,000 animals at Project Agropolitan
